Otto T - Search Results

1

mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.

Gerullis H, Ecke TH, Eimer C, Heuck CJ, Otto T. Gerullis H, et al. Among authors: otto t. Minerva Urol Nefrol. 2010 Dec;62(4):411-23. Minerva Urol Nefrol. 2010. PMID: 20944541 Review.

2

Targeted agents in second-line bladder cancer therapy.

Gerullis H, Otto T, Ecke TH. Gerullis H, et al. Among authors: otto t. Anticancer Drugs. 2012 Nov;23(10):1003-15. doi: 10.1097/CAD.0b013e3283582a33. Anticancer Drugs. 2012. PMID: 22914698 Review.

3

Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.

Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T. Gerullis H, et al. Among authors: otto t. Anticancer Drugs. 2013 Apr;24(4):422-5. doi: 10.1097/CAD.0b013e32835efe78. Anticancer Drugs. 2013. PMID: 23407060 Clinical Trial.

4

Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.

Gerullis H, Bergmann L, Maute L, Eimer C, Otto T. Gerullis H, et al. Among authors: otto t. Cancer Chemother Pharmacol. 2009 May;63(6):1097-102. doi: 10.1007/s00280-008-0835-2. Epub 2008 Sep 26. Cancer Chemother Pharmacol. 2009. PMID: 18818922

5

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW, Otto T. Gerullis H, et al. Among authors: otto t. Med Oncol. 2010 Jun;27(2):373-8. doi: 10.1007/s12032-009-9220-1. Epub 2009 Apr 28. Med Oncol. 2010. PMID: 19399651

6

Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.

Gerullis H, Ecke T, Eimer C, Wishahi M, Otto T. Gerullis H, et al. Among authors: otto t. Anticancer Drugs. 2011 Jan;22(1):9-17. doi: 10.1097/CAD.0b013e3283404db0. Anticancer Drugs. 2011. PMID: 20948429 Review.

7

mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?

Eimer C, Gerullis H, Heuck C, Otto T. Eimer C, et al. Among authors: otto t. Anticancer Drugs. 2011 Jan;22(1):18-23. doi: 10.1097/CAD.0b013e3283407dde. Anticancer Drugs. 2011. PMID: 21037468 Review.

8

Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.

Gerullis H, Ecke TH, Janusch B, Arndt C, Heidari M, Oniani J, Otto T. Gerullis H, et al. Among authors: otto t. Anticancer Drugs. 2011 Oct;22(9):940-3. doi: 10.1097/CAD.0b013e328347a86a. Anticancer Drugs. 2011. PMID: 21642839

9

A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

Gerullis H, Eimer C, Ecke TH, Georgas E, Freitas C, Kastenholz S, Arndt C, Heusch C, Otto T. Gerullis H, et al. Among authors: otto t. Med Oncol. 2012 Dec;29(4):2870-6. doi: 10.1007/s12032-012-0216-x. Epub 2012 Mar 25. Med Oncol. 2012. PMID: 22447503 Clinical Trial.

10

Temsirolimus in renal cell carcinoma.

Otto T, Eimer C, Gerullis H. Otto T, et al. Transplant Proc. 2008 Dec;40(10 Suppl):S36-9. doi: 10.1016/j.transproceed.2008.10.006. Transplant Proc. 2008. PMID: 19100905

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

698 results

Search Page

Filters